Please login to the form below
gram-negative bacteria
This page shows the latest gram-negative bacteria news and features for those working in and with pharma, biotech and healthcare.
UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme
The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Fetcroja was launched in the UK in
Latest news
-
MSD launches antibiotic combo Recarbrio in UK
Therapeutic indicated to treat infections caused by Gram-negative bacteria. MSD (also known as Merck &Co) has launched its novel antibiotic combination Recarbrio in the UK. ... In a pivotal phase 3 trial of adult patients with infections caused by
-
Shionogi’s novel antibiotic trial data published in The Lancet
The APEKS-NP study evaluated Fetcroja in severely ill patients with hospital-acquired, ventilator-associated or healthcare-associated pneumonia caused by a broad range of Gram-negative bacteria. ... Fetcroja launched in the UK in September, launching as
-
Shionogi's Gram-negative antibiotic launches in the UK
aerobic Gram-negative bacteria in adults. ... all Gram-negative pathogens considered to be of 'critical priority' by the World Health Organization.
-
Modest meeting sees only two drugs recommended by CHMP
The CHMP recommended a marketing authorisation of Japanese pharma company Shionogi’s antimicrobial drug Fetcroja (cefiderocol) for the treatment of infections caused by Gram-negative organisms in adults with limited treatment ... This allows it to
-
FDA accepts priority review for Merck’s antibiotic combo Recarbrio
Gram-negative bacteria are increasingly becoming a huge global health problem, causing prolonged hospital stays and steep healthcare costs. ... The World Health Organization (WHO) has highlighted “in particular the threat of gram-negative bacteria that
More from news
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2016
using Warp's SMART and genome mining platforms for the discovery of oncology therapeutics and antibiotics targeting Gram negative bacteria.
-
Deal Watch table for February 2014
270. Discuva / Roche. Collaboration. Antibiotics to target multi-drug resistant Gram negative bacteria.
-
Pharma deals during February 2014
BATON studies in colorectal cancer and metastatic triple negative breast cancer. ... In the meantime, Roche's pRED group will make use of Discuva's development technology, which uses gene sequencing and bioinformatics to identify targets for multi-drug
-
Pharma deals during March 2013
This combined intravenous therapy is currently undergoing phase III clinical trials as a potential first-line treatment for complicated intra-abdominal and urinary tract infections caused by certain Gram-negative bacteria, ... Astellas Pharma/ Cubist
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- How Resonant’s innovation and creativity resolve healthcare communications challenges
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
Madmicrobe Studios - Medical Animation
MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
